200 Participants Needed

Combined Therapies for PTSD

Recruiting at 2 trial locations
MS
JC
Overseen ByJohn C Fortney, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: VA Office of Research and Development
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores new treatments for PTSD (Posttraumatic Stress Disorder) in Veterans at high risk of suicide. It compares a combined therapy approach using Dialectical Behavior Therapy (DBT) and a specialized Prolonged Exposure protocol (DBT PE) with the current standard treatment, which includes Prolonged Exposure therapy and suicide risk management. The researchers aim to determine if the combined therapy more effectively improves PTSD symptoms and reduces suicide risk. Veterans with PTSD who struggle with emotional control and have recently experienced suicidal thoughts or actions may be suitable for this study. The results will inform treatment guidelines for Veterans facing these challenges. As an unphased trial, this study offers Veterans the chance to contribute to groundbreaking research that could enhance future PTSD treatments.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that combining Dialectical Behavior Therapy (DBT) with the DBT Prolonged Exposure (DBT PE) protocol is generally safe for treating PTSD. Studies indicate that this treatment improves symptoms without causing major side effects. Specifically, one study found that individuals who completed the DBT PE protocol were much less likely to attempt suicide or self-harm compared to those who only received standard DBT.

Prolonged Exposure therapy (PE) with suicide risk management (SRM) is another well-established treatment for PTSD. It is considered safe and effective in reducing trauma symptoms. Research also shows that PE decreases thoughts and actions related to suicide, making it a reliable option for those with PTSD, especially when combined with SRM.

Both treatments have strong support from studies, which suggest they are well-tolerated and effective in improving PTSD symptoms and reducing the risk of suicide.12345

Why are researchers excited about this trial's treatments?

Researchers are excited about these combined therapies for PTSD because they're testing unique approaches to tackle the condition. Unlike standard treatments that often use one type of therapy, this trial combines Dialectical Behavior Therapy (DBT) with a specialized Prolonged Exposure protocol (DBT PE) for a comprehensive approach. Another treatment arm in the study uses Prolonged Exposure therapy enhanced with suicide risk management, which brings a dual focus on trauma and immediate safety. These innovative combinations aim to enhance treatment effectiveness by addressing both emotional regulation and trauma exposure, offering new hope for those with PTSD.

What evidence suggests that this trial's treatments could be effective for PTSD?

Research shows that combining Dialectical Behavior Therapy (DBT) with the DBT Prolonged Exposure protocol (DBT PE) effectively treats PTSD. Studies have found that DBT PE can significantly reduce PTSD symptoms and improve patients' quality of life. One study showed that 58% of patients experienced symptom remission compared to 41% with other treatments. In this trial, one group of participants will receive the combination of DBT and DBT PE.

Another group will receive Prolonged Exposure therapy (PE) combined with suicide risk management (SRM). Research indicates that this combination effectively reduces PTSD symptoms and suicidal thoughts. Success rates for PE range from 65% to 80%, highlighting its effectiveness. Both approaches have strong evidence supporting their ability to improve PTSD outcomes.12356

Who Is on the Research Team?

MS

Melanie S Harned, PhD

Principal Investigator

VA Puget Sound Health Care System Seattle Division, Seattle, WA

Are You a Good Fit for This Trial?

This trial is for Veterans with PTSD who are at risk of suicide. They must be eligible for VHA mental health care, have emotion dysregulation and recent self-harm, be over 18, willing to participate in all study activities, and currently have suicidal thoughts. Those already treated with DBT or PE recently, unable to stay safe on their own, planning to move away soon or unable to understand the study due to language or cognitive issues can't join.

Inclusion Criteria

I am currently having thoughts about harming myself.
Recent and repeated self-directed violence
Emotion dysregulation
See 3 more

Exclusion Criteria

I have been receiving DBT or PE therapy in the past year.
I will be available and not planning to move for the next 18 months.
I cannot ensure my own safety without help.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either DBT + DBT PE or PE + SRM for PTSD and suicide risk management

12 months for DBT + DBT PE, up to 18 sessions for PE + SRM
Regular outpatient visits

Follow-up

Participants are monitored for safety and effectiveness after treatment

18 months
5 assessment points

Implementation Evaluation

Evaluation of barriers and facilitators to implementation of treatments

Concurrent with treatment phase

What Are the Treatments Tested in This Trial?

Interventions

  • Dialectical Behavior Therapy
  • Dialectical Behavior Therapy Prolonged Exposure protocol
  • Prolonged Exposure therapy
  • Suicide risk management
Trial Overview The trial tests if combining Dialectical Behavior Therapy (DBT) with a specific protocol called DBT Prolonged Exposure (PE) is more effective than just Prolonged Exposure therapy plus suicide risk management in reducing PTSD symptoms and suicidal behavior among Veterans.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: DBT + DBT PEExperimental Treatment2 Interventions
Group II: PE + SRMActive Control2 Interventions

Dialectical Behavior Therapy is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as DBT for:
🇪🇺
Approved in European Union as DBT for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

VA Office of Research and Development

Lead Sponsor

Trials
1,691
Recruited
3,759,000+

Published Research Related to This Trial

In a study of 31 combat veterans with PTSD undergoing prolonged exposure therapy, 9 out of 24 completers achieved complete remission from PTSD, indicating the therapy's potential efficacy.
The study found that successful remission from PTSD was associated with decreased activation in the left anterior insula during negative image anticipation and increased connectivity with other brain regions, suggesting that effective treatment may involve better regulation of anticipatory anxiety.
Neurosubstrates of remission following prolonged exposure therapy in veterans with posttraumatic stress disorder.Simmons, AN., Norman, SB., Spadoni, AD., et al.[2021]
A formative evaluation of 38 VA residential treatment programs for PTSD revealed that a significant number of providers received training in evidence-based treatments (EBTs) for PTSD, with 37.4% trained in prolonged exposure (PE) and 64.2% in cognitive processing therapy (CPT).
The adoption of these EBTs varied widely among programs, indicating a need for strategies to enhance implementation, such as simplifying treatment manuals to focus on essential elements.
A formative evaluation of two evidence-based psychotherapies for PTSD in VA residential treatment programs.Cook, JM., O'Donnell, C., Dinnen, S., et al.[2021]
In a study of 38 women with borderline personality disorder (BPD) and PTSD, adding the DBT Prolonged Exposure (DBT PE) protocol to standard Dialectical Behavior Therapy (DBT) significantly improved PTSD symptoms during Stage 2 and enhanced overall well-being in Stage 3.
The results suggest that targeting PTSD directly is crucial for improving related issues, as changes in other problems like BPD and dissociation occurred only after PTSD treatment, indicating that DBT PE is a beneficial addition to standard DBT for these patients.
What changes when? The course of improvement during a stage-based treatment for suicidal and self-injuring women with borderline personality disorder and PTSD.Harned, MS., Gallop, RJ., Valenstein-Mah, HR.[2020]

Citations

Does Adding the Dialectical Behavior Therapy Prolonged ...Although these studies suggest that adding the DBT PE protocol to DBT is feasible, safe, and likely to improve PTSD and other outcomes, the generalizability of ...
A systematic review and meta-analysis on the efficacy of ...Conclusions: Based on the results of our meta-analysis, DBT-PTSD and DBT PE were effective in reducing PTSD symptom severity and comorbid ...
Dialectical Behavior Therapy Prolonged Exposure (DBT ...DBT PE improved quality of life, life worth living, radical acceptance of trauma. •. Evidence-based protocols can benefit from a minority stress ...
ResearchPerspectives on a stage-based treatment for posttraumatic stress disorder among Dialectical Behavior Therapy consumers in public mental health settings.
Dialectical Behavior Therapy for Posttraumatic Stress ...The proportions achieving symptomatic remission were 58% in DBT-PTSD vs 41% in CPT, a significant difference. Meaning In this trial, patients ...
A pilot randomized controlled trial of Dialectical Behavior ...Patients who completed the DBT PE protocol were 2.4 times less likely to attempt suicide and 1.5 times less likely to self-injure than those in DBT. Among ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security